As per a study released today in the European Heart Journal, females should be properly included in cardiovascular illness studies to guarantee that therapy suggestions reflect their individual health requirements. The study examines the challenges of enrolling females into medical studies as well as workable issues.

Cardiovascular diseases (CVDs) are Europe’s largest source of death, representing 47 percent of all fatalities in females and 39 percent of all fatalities in males, correspondingly. “Although there have been significant advances in reducing CVD-related morbidity and mortality in both sexes, the current guideline-directed therapies is based on data that predominantly include male patients. Consequently, in CVD management women patients might currently be treated equally (the same), however, they are not treated based on equity”.

Female Participation In Cardiovascular Clinical Trials

The researchers conducted a thorough review of the research for publications that addressed the motivating factors, enablers, and obstacles to enrollment and involvement. Only relevant studies were discovered, with a combination of 846 males and 1,122 females.

This ratio itself speaks a lot. A more number of females are needed for such trials as they can help the experts find reasons and better options to avoid the possible cardiovascular issues in a patient. The fewer number of female participants is a concern for not only researchers but the whole medical community and in the interest of future patients.

Increase Female Participation In Cardiovascular Clinical Trials

“For many years it was usual practice that studies on heart disease primarily included white men,” said author Dr. Jeske van Diemen of Amsterdam University Medical Centre. “It was assumed that the results were also relevant to women and other races but the evidence is emerging that this is not the case.

For instance, female heart patients have a greater risk of adverse drug reactions compared with male patients, and these reactions are generally more serious. Similarly, it has been suggested that women with heart failure may need lower doses of medications than their male counterparts.”

The chance of receiving greater and much more consistent treatment, as well as humanitarian ideals like the wish to advance research, were all motivating factors both for males and females. Neither of the research looked into how to increase female’s sign-up percentages.

The researchers did notice, however, that a higher socioeconomic status was linked to a greater desire to engage amongst females. According to them, this could marginalize females of lower social backgrounds, who would gain the greatest from greater participation.

Jeske van Diemen added: “Within our own research group we noticed how hard it was to recruit women. We, therefore, decided to examine current evidence on reasons to agree or decline participation, with the aim of coming up with solutions to increase gender balance in cardiovascular trials.”

According to the researchers, a varied staff is more able to interpret and customize studies to different groups. Female involvement participation in the development and execution of cardiac trials may help with enrollment in this regard. Transport to clinical research locations and site daycare are examples of material support that may be beneficial.

Dr. van Diemen said: “It was an eye-opener for me that women seem to have a different assessment of the risks involved in participating in trials, and consider it riskier than men do. In addition, women more often have barriers which make it difficult to attend follow-up appointments—such as not holding a driving license or caring for grandchildren.”

She concluded: “Currently we treat many patients as if they were the same, which of course is not the case. Study populations that better represent the demographics of society should lead to more relevant findings that improve cardiovascular outcomes for everyone.”